FDA/FTC or a state medical board issues a public warning or enforcement action targeting at-home ketamine telehealth prescribing standards by mid-November 2026.

The FDA (the US drug regulator) or the FTC (the US consumer protection agency), or a state medical board, is expected to publicly call out or punish companies that prescribe ketamine online and have it mailed to patients' homes. Regulators have been building a case based on documented safety concerns, including children accidentally getting into these medications. A formal warning or enforcement action is predicted before November 15, 2026.

The Ontario liability-waiver suspension plus rising pediatric ingestion cases create a regulatory paper trail. Agencies act on documented harm patterns, not hype. This is the kind of signal that forces guidance.